Farlow MR - Search Results

1

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ. Aisen PS, et al. Among authors: farlow mr. Neurology. 2000 Feb 8;54(3):588-93. doi: 10.1212/wnl.54.3.588. Neurology. 2000. PMID: 10680787 Clinical Trial.

2

Clinical characteristics in a kindred with early-onset Alzheimer's disease and their linkage to a G-->T change at position 2149 of the amyloid precursor protein gene.

Farlow M, Murrell J, Ghetti B, Unverzagt F, Zeldenrust S, Benson M. Farlow M, et al. Neurology. 1994 Jan;44(1):105-11. doi: 10.1212/wnl.44.1.105. Neurology. 1994. PMID: 8290042

3

Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway.

Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B, Nee L, Pulaski-Salo D, Dickson D, Robitaille Y, Bergeron C, Crain B, Benson MD, Farlow M, Hyman BT, George-Hyslop SP, Roses AD, Pollen DA. Lippa CF, et al. Neurology. 1996 Feb;46(2):406-12. doi: 10.1212/wnl.46.2.406. Neurology. 1996. PMID: 8614503

4

Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.

Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Schneider LS, et al. Among authors: farlow mr. Neurology. 1996 Jun;46(6):1580-4. doi: 10.1212/wnl.46.6.1580. Neurology. 1996. PMID: 8649552 Clinical Trial.

5

Alzheimer's disease: clinical implications of the apolipoprotein E genotype.

Farlow MR. Farlow MR. Neurology. 1997 May;48(5 Suppl 6):S30-4. doi: 10.1212/wnl.48.5_suppl_6.30s. Neurology. 1997. PMID: 9153158 Review.

6

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. Rogers SL, et al. Among authors: farlow mr. Neurology. 1998 Jan;50(1):136-45. doi: 10.1212/wnl.50.1.136. Neurology. 1998. PMID: 9443470 Clinical Trial.

7

Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.

Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Farlow MR, et al. Neurology. 1998 Mar;50(3):669-77. doi: 10.1212/wnl.50.3.669. Neurology. 1998. PMID: 9521254 Clinical Trial.

8

Pharmacologic treatment of cognition in Alzheimer's dementia.

Farlow MR, Evans RM. Farlow MR, et al. Neurology. 1998 Jul;51(1 Suppl 1):S36-44; discussion S65-7. doi: 10.1212/wnl.51.1_suppl_1.s36. Neurology. 1998. PMID: 9674761 Review.

9

Clinical trials in Alzheimer disease: debate on the use of placebo controls.

Kawas CH, Clark CM, Farlow MR, Knopman DS, Marson D, Morris JC, Thal LJ, Whitehouse PJ. Kawas CH, et al. Among authors: farlow mr. Alzheimer Dis Assoc Disord. 1999 Jul-Sep;13(3):124-9. doi: 10.1097/00002093-199907000-00002. Alzheimer Dis Assoc Disord. 1999. PMID: 10485569 Review.

10

Metrifonate treatment of AD: influence of APOE genotype.

Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Gulanski B. Farlow MR, et al. Neurology. 1999 Dec 10;53(9):2010-6. doi: 10.1212/wnl.53.9.2010. Neurology. 1999. PMID: 10599773 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

525 results

Search Page

Filters